Trials
1 active
5 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 will be administered by intravenous (IV) infusion over six months and continued for an additional 20 months for…”In the company’s words, NCT05322590 on ClinicalTrials.gov
- Tested for
- Metastatic Colorectal Carcinoma, Neuropathy
- Main trialPhase 1/2
- “The study will assess the safety and efficacy of BXQ-350 plus modified FOLFOX7 (mFOLFOX7) and bevacizumab in participants who have newly diagnosed metastatic adenocarcinoma of the colon/rectum. The study will also evaluate if the administration of BXQ-350 with mFOLFOX7 and bevacizumab may diminish oxaliplatin induced sensory neurotoxicity, enabling participants to receive the total and planned doses of mFOLFOX7. All participants will receive BXQ-350 by intravenous (IV) infusion along with standard of care doses of mFOLFOX and bevacizumab. The study is divided into two stages: Stage 1 will be…”In the company’s words, NCT05322590 on ClinicalTrials.gov
- Other names
- SapC-DOPS
Other drugs for Metastatic Colorectal Carcinoma
- DostarlimabGSK · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- GRT-C901Seattle Project Corporation · Phase 2/3
- GRT-R902Seattle Project Corporation · Phase 2/3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- NuvastaticNatureceuticals Sdn Bhd · Phase 3
Coming up1
- NovPhase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | Nov 2026 | BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma | |
| Phase 1Completed | 17 Jun 2019 | Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors | |
| Phase 1Terminated | 3 Jan 2020 | A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors | |
| Phase 1Terminated | 23 Sep 2024 | Continued Treatment for Participants Enrolled in Studies of BXQ-350 | |
| Phase 1Terminated | 4 Oct 2024 | A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026